Q3 2025 Financial Results and Product Highlights of 32 Global Pharmaceutical Giants Including Eli Lilly, Novo Nordisk, Pfizer, MSD, Johnson & Johnson, and AstraZeneca

Note: The fiscal year start dates of major companies differ from the calendar year, so there may be inconsistencies between fiscal quarters, years, etc., and the calendar year.

United States

Eli Lilly and Company announced its financial results for the third quarter of 2025. Quarterly revenue reached $17.6 billion, compared to $11.439 billion in the same period last year, representing a year-over-year increase of 54%. The quarterly operating profit was $7.365 billion, up from $1.526 billion in the same period last year. Net profit for the quarter was $5.583 billion, compared to $970 million in the same period last year.

Pfizer Announces Q3 2025 Results. Total revenue for the quarter was $16.654 billion, compared to $17.702 billion in the same period last year, representing a 6% decrease. Operating profit from continuing operations for the quarter was $3.55 billion, down 21% from $4.481 billion in the same period last year. Net profit attributable to the company's ordinary shareholders for the quarter was $3.541 billion, a 21% decrease from $4.465 billion in the same period last year.

Merck (MSD) Announces Q3 2025 Results. Quarterly sales reached $17.276 billion, compared to $16.657 billion in the same period last year, representing a 4% increase. Quarterly net profit was $5.785 billion, up 83% from $3.157 billion in the same period last year. Pharmaceutical sales amounted to $15.611 billion, compared to $14.943 billion in the same period last year, an increase of 4%. Animal health sales were $1.615 billion, compared to $1.487 billion in the same period last year, marking a 9% growth.

Johnson & Johnson Announces Q3 2025 ResultsQuarterly sales reached $23.993 billion, compared to $22.471 billion in the same period last year, representing a 6.8% year-over-year increase. Quarterly net profit was $5.152 billion, up from $2.694 billion in the same period last year, marking a 91.2% year-over-year increase. Adjusted net profit was $6.801 billion, compared to $5.876 billion in the same period last year, reflecting a 15.7% year-over-year increase. Sales from the innovative pharmaceuticals business were $15.563 billion, up 6.8% year-over-year. Sales from the medical devices business were $8.43 billion, also reflecting a 6.8% year-over-year increase.

AbbVie Reports Third Quarter 2025 Results. Net revenue for the quarter was $15.776 billion, compared to $14.46 billion in the same period last year. Operating profit for the quarter was $1.904 billion, compared to $3.831 billion in the same period last year. Net profit attributable to the company for the quarter was $186 million, compared to $1.561 billion in the same period last year.

Bristol Myers Squibb announced its financial results for the third quarter of 2025. Total revenue for the quarter was $12.22 billion, compared to $11.89 billion in the same period last year. Net profit attributable to the company for the quarter was $2.201 billion, compared to $1.211 billion in the same period last year.

Biotech Company Amgen Announces Q3 2025 Results. Total revenue for the quarter was $9.557 billion, compared to $8.503 billion in the same period last year. Operating profit for the quarter was $2.526 billion, compared to $2.047 billion last year. Net profit for the quarter was $3.216 billion, compared to $2.83 billion last year.

Gilead Sciences Announces Q3 2025 Financial Results. Total revenue for the quarter was $7.769 billion, compared to $7.545 billion in the same period last year. Operating profit for the quarter was $3.327 billion, compared to $888 million in the same period last year. Net profit attributable to the company for the quarter was $3.052 billion, compared to $1.253 billion in the same period last year.

Viatris Releases Financial Results for the Third Quarter of 2025. Total revenue for the quarter was $3.76 billion, compared to $3.751 billion in the same period last year. Operating profit for the quarter was $179 million, compared to $226 million in the same period last year. Net loss for the quarter was $128 million, compared to a net profit of $94.8 million in the same period last year.

Regeneron Announces Third Quarter 2025 Results. Quarterly revenue was $3.754 billion, compared to $3.721 billion in the same period last year. Quarterly operating profit was $1.027 billion, compared to $1.18 billion last year. Quarterly net profit was $1.46 billion, compared to $1.341 billion last year.

Vertex Pharmaceuticals Announces Q3 2025 Results. Total revenue for the quarter was $3.076 billion, compared to $2.772 billion in the same period last year. Operating profit for the quarter was $1.186 billion, compared to $1.116 billion last year. Net profit for the quarter was $1.083 billion, compared to $1.045 billion in the same period last year.

Biogen Reports Q3 2025 Financial Results. Total revenue for the quarter was $2.535 billion, compared to $2.466 billion in the same period last year. Net income attributable to the company for the quarter was $467 million, compared to $389 million in the same period last year.

Organon announced its financial results for the third quarter of 2025. Revenue for the quarter was $1.602 billion, compared to $1.582 billion in the same period last year. The net profit for the quarter was $160 million, compared to $359 million in the same period last year.

Abbott Announces Q3 2025 Financial Results. Net sales for the quarter were $11.369 billion, compared to $10.635 billion in the same period last year, representing a 6.9% year-over-year increase. Operating profit for the quarter was $2.057 billion, up from $1.859 billion in the same period last year, marking a 10.6% year-over-year growth. Net profit for the quarter was $1.644 billion, compared to $1.646 billion in the same period last year. Specifically, sales from the nutrition business were $2.153 billion, diagnostic business sales were $2.253 billion, pharmaceuticals business sales were $1.511 billion, and medical devices business sales were $5.369 billion.

Europe

AstraZeneca announced its financial results for the third quarter of 2025. Total revenue for the quarter was $15.191 billion, compared to $13.565 billion in the same period last year, representing a 12% year-over-year increase. Operating profit for the quarter was $3.583 billion, up from $2.106 billion in the same period last year, marking a 70% year-over-year increase. Net profit after tax for the quarter was $2.535 billion, compared to $1.433 billion in the same period last year, reflecting a 77% year-over-year increase.

Roche Announces Financial Results for the First Nine Months of 2025. During this period, the group's sales revenue reached 45.862 billion Swiss francs. Among which, pharmaceutical business sales amounted to 35.555 billion Swiss francs (approximately 44.9 billion US dollars), and diagnostic business sales were 10.307 billion Swiss francs. In the third quarter, the group’s sales revenue was 14.918 billion Swiss francs, compared to 15.136 billion Swiss francs in the same period last year. Specifically, pharmaceutical business sales were 11.57 billion Swiss francs (approximately 14.6 billion US dollars), compared to 11.62 billion Swiss francs in the same period last year. Diagnostic business sales were 3.348 billion Swiss francs, compared to 3.516 billion Swiss francs in the same period last year.

Sanofi Announces Q3 2025 Results. Net Sales for the Quarter Reach €12.424 Billion (Approx. $14.5 Billion), Compared to €12.157 Billion in the Same Period Last Year, a Year-on-Year Increase of 2.3%. Operating Profit for the Quarter Totals €3.623 Billion, Compared to €3.539 Billion in the Prior Year. Net Profit Attributable to Shareholders for the Quarter Amounts to €2.802 Billion, Down 0.5% from €2.815 Billion in the Same Period Last Year.

Novartis Announces Q3 2025 Results. Net sales for the quarter were $13.909 billion, compared to $12.823 billion in the same period last year, representing an 8% increase. Operating income for the quarter was $4.501 billion, compared to $3.627 billion in the same period last year, a 24% increase. Net profit for the quarter was $3.93 billion, compared to $3.185 billion in the same period last year, a 23% increase.

Novo Nordisk Releases Q3 2025 Financial Results. Net sales for the quarter reached DKK 74.976 billion (approximately USD 11.7 billion), compared to DKK 71.311 billion in the same period last year, representing a 5% increase. Operating profit for the quarter was DKK 23.682 billion, down 30% from DKK 33.822 billion in the same period last year. Net profit for the quarter was DKK 20.006 billion, a 27% decrease from DKK 27.301 billion in the same period last year.

GSK Releases Q3 2025 Financial Results. Quarterly revenue reached £8.547 billion (approximately $11.2 billion), compared to £8.012 billion in the same period last year. Quarterly operating profit was £2.593 billion, versus £189 million in the previous year. Net profit attributable to shareholders for the quarter was £2.013 billion, compared to a net loss of £58 million in the same period last year.

Bayer Group Announces Q3 2025 Results. Group sales for the quarter reached €9.66 billion, compared to €9.968 billion in the same period last year. EBIT loss for the quarter was €543 million, compared to a loss of €3.822 billion in the same period last year. Net special charges amounted to €1.064 billion, compared to €4.088 billion in the prior-year quarter, primarily related to litigation provisions. Net loss for the quarter was €963 million, compared to €4.183 billion in the same period last year. By segment, Crop Science sales were €3.858 billion, with an EBIT loss of €1.187 billion. Pharmaceuticals sales reached €4.335 billion (approximately $5.045 billion), with EBIT profit of €758 million. Consumer Health sales were €1.415 billion, with EBIT profit of €262 million.

German pharmaceutical and chemical giant Merck Group announced its financial results for the third quarter of 2025. Net sales for the quarter reached €5.318 billion, compared to €5.266 billion in the same period last year. Operating profit (EBIT) for the quarter was €1.221 billion, up 11.3% from €1.097 billion in the same period last year. Net profit after tax for the quarter was €898 million, an increase of 10.6% from €812 million in the same period last year. Among these figures, Life Science business net sales were €2.241 billion (approximately $2.61 billion), Healthcare business net sales were €2.203 billion (approximately $2.564 billion), and Electronics Technology business net sales were €875 million.

Sandoz Reports Q3 2025 Results. Net sales for the third quarter were $2.825 billion, compared to $2.595 billion in the same period last year. Net sales for the first nine months were $8.057 billion, compared to $7.642 billion in the same period last year.

Fresenius Group Announces Q3 2025 Financial ResultsFresenius Group (FRESENIUS GROUP) released its financial results for the third quarter of 2025. The group's revenue for the quarter was €5.477 billion, compared to €5.303 billion in the same period last year. Quarterly EBIT profit reached €574 million, up from €552 million in the previous year. Net profit attributable to shareholders of the company for the quarter was €461 million, compared to €388 million in the same period last year. Among this, Fresenius Kabi reported revenue of €2.141 billion (approximately $2.49 billion) and an EBIT profit of €358 million. Fresenius Helios Clinics achieved revenue of €3.24 billion and an EBIT profit of €242 million.

Grifols Announces Third Quarter Results for 2025. Net revenue for the quarter was €1.865 billion (approximately $2.17 billion), with an adjusted EBITDA profit of €482 million and a group net profit of €127 million. For the first nine months, net revenue was €5.542 billion (approximately $6.49 billion), with an adjusted EBITDA profit of €1.358 billion and a group net profit of €304 million.

Specialty pharmaceutical company Ipsen announced its Q3 2025 results. Total sales for the quarter reached €915 million (approximately $1.065 billion), compared to €837 million in the same period last year. Oncology business sales were €624 million, rare disease business sales were €102 million, and neuroscience business sales amounted to €189 million.

Asia-Pacific

Takeda Pharmaceutical Company Limited announced its financial results for the first half of the fiscal year ending September 30, 2025 (April-September). Revenue for the period was 2,219.481 billion yen (approximately 14.4 billion U.S. dollars), compared to 2,384.028 billion yen in the same period last year, representing a decrease of 6.9%. Operating profit for the quarter was 253.561 billion yen, compared to 350.576 billion yen in the same period last year, a decrease of 27.7%. Net profit attributable to owners of the parent company for the quarter was 112.441 billion yen, compared to 187.294 billion yen in the same period last year, a decrease of 40%.

Teva Pharmaceutical Industries announced its financial results for the third quarter of 2025. The net revenue for the quarter was $4.48 billion, compared to $4.332 billion in the same period last year. The operating profit for the quarter was $882 million, while there was an operating loss of $51 million in the same period last year. The net profit attributable to the company for the quarter was $433 million, compared to a net loss of $437 million in the same period last year.

Astellas Pharma Announces Financial Results for the First Half of Fiscal Year Ending September 30, 2025 (April-September). Revenue for the period was 1,030.114 billion yen (approximately 6.67 billion USD), compared to 935.621 billion yen in the same period last year. Quarterly operating profit was 199.378 billion yen, compared to 93.71 billion yen in the previous year. Quarterly net profit attributable to owners of the parent company was 147.635 billion yen, compared to 73.511 billion yen in the same period last year.

Daiichi Sankyo Company, Limited Announces Financial Results for the First Half of the Fiscal Year Ending September 30, 2025 (April-September). Revenue for the period was 975.353 billion yen (approximately 6.32 billion USD), compared to 882.727 billion yen in the same period last year, representing a year-on-year increase of 10.5%. Operating profit for the quarter was 144.237 billion yen, down 22.8% from 186.9 billion yen in the same period last year. Net profit attributable to owners of the parent company for the quarter was 130.814 billion yen, a decrease of 10.8% compared to 146.675 billion yen in the same period last year.

Otsuka Holdings Co., Ltd. Announces Financial Results for the First Nine Months of 2025. Revenue for the period was 1,818.743 billion yen, compared to 1,730.076 billion yen in the same period last year, representing a year-on-year increase of 5.1%. Operating profit reached 407.421 billion yen, up from 261.045 billion yen in the same period last year, marking a year-on-year growth of 56.1%. Net profit attributable to owners of the parent company was 297.658 billion yen, compared to 191.672 billion yen in the same period last year, reflecting a year-on-year increase of 55.3%. Pharmaceutical business revenue amounted to 1,278.68 billion yen (approximately 8.28 billion USD), nutrition business revenue was 430.767 billion yen, and consumer goods business revenue was 25.811 billion yen.

Eisai Co., Ltd. Announces Financial Results for the First Half of the Fiscal Year Ending September 30, 2025 (April-September). Revenue for the period was 400.13 billion yen (approximately 2.59 billion USD), compared to 385.023 billion yen in the same period last year, representing a 3.9% increase. Operating profit for the period was 34.418 billion yen, compared to 27.837 billion yen in the same period last year, marking a 23.6% increase. Net profit attributable to owners of the parent company for the period was 24.63 billion yen, compared to 21.693 billion yen in the same period last year, reflecting a 13.5% increase.